Skip to main content
  • Praluent Delivers CV Event Prevention in ODYSSEY

    Second PCSK9 outcomes trial comes out like FOURIER -- but with mortality reduction

    This story was originally published March 10, 2018. As part of MedPage Today's year-end review of 2018's top stories, we are republishing it along with an update on what has happened since with the PCSK9 inhibitors.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details